For the quarter ending 2025-03-31.
| Income Statement | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total revenues | - | 7,681 | 13,534 | 8,967 |
| Share of collaboration loss | - | -1,138 | - | - |
| Selling, general and administrative | - | 10,592 | 12,884 | 9,857 |
| Research and development | - | 26,292 | 8,320 | 16,013 |
| Change in fair value of contingent consideration | - | -577 | - | -685 |
| Restructuring expenses | - | 2,201 | 503 | 7,398 |
| Cost of manufacturing for commercial collaboration | - | 4,395 | 5,768 | 3,453 |
| Total operating expenses | 0 | 44,891 | 27,475 | 36,036 |
| Loss from operations | 0 | -37,210 | -13,941 | -27,069 |
| Other income, net | - | 880 | 1,153 | 1,434 |
| Interest income, net | - | 2,747 | 2,855 | 2,527 |
| Gain (loss) on sale of assets | - | -1,675 | - | 47,987 |
| Loss before income taxes | - | -36,096 | -9,933 | 24,879 |
| Net loss | - | -36,096 | -9,933 | 24,879 |
| Other comprehensive income, net of tax benefit (expense) of 0.0million and 0.0million for the years ended december31, 2024 and 2023, respectively | - | -174 | 541 | 100 |
| Comprehensive loss | - | -36,270 | -9,392 | 24,979 |
| Basic eps | 0.01 | -0.695 | -0.19 | 0.48 |
| Diluted eps | 0.01 | -0.68 | -0.19 | 0.45 |
| Basic average shares | 53,055,000 | -26,115,500 | 52,263,000 | 52,186,000 |
| Diluted average shares | 53,433,000 | -27,528,000 | 52,263,000 | 55,011,000 |
null (TSVT)
null (TSVT)